Vytoringate Builds Steam – Folic Acid Ignored
Friday, January 25, 2008
Board Certified Clinical Nutritionist Byron J. Richards,
The Wall Street Journal now calls it Vytoringate – one of the biggest drug frauds in history. Merck and Schering-Plough sat on bad drug trial results of their cholesterol drug and raked in close to 10 billion dollars selling snake oil. The drug in question, Vytorin, was supposed to prove it could reduce heart disease risk by lessening the thickness in the carotid artery, thus showing the ability to reduce plaque formation. It failed miserably. As I have reported, the statin Class of drugs aka HMG-CoA reductase inhibitors, that are used to lower cholesterol levels by inhibiting the HMG-CoA reductase enzyme that plays a central role in liver function and cholesterol production. industry is one big scam.
The House Subcommittee on Oversight and Investigations is looking into the matter. The fry pan is getting hot. Congressmen Bart Stupak and John Dingell have written a letter to the companies asking questions and stating “We have … discovered that a Schering-Plough officer, Carrie Smith Cox, sold significant numbers of shares of Schering-Plough in the time between the end of the ENHANCE study and the release of the results on January 14, 2008.”
Now the Senate is getting involved. The Wall Street Journal reports that Senator Chuck Grassley has sent a batch of letters to the SEC, the American Heart Association (AHA), the American College of Cardiology (ACC) and the CEOs of Merck and Schering-Plough. Yes, the same folks who have fraudulently attacked vitamin E and cost many elderly their health were most likely in on the hoax – promoting the sale of bogus cholesterol drugs under the fraudulent shield of “impartial science.”
Not to be outdone by the Senate, Dingell and Stupak chimed in: “Given the AHA’s and ACC’s recent statements on Vytorin and the ENHANCE study, our Committee is interested to learn what financial arrangements exist between the marketers of Vytorin and these two organizations,” Dingell said in a statement. “The public places great trust in the official views of the AHA and the ACC, so it is important to verify that these views have not been compromised by a financial relationship with the pharmaceutical industry.”
Meanwhile, nobody seems to be mentioning that folic acid has already been proven to do what Vytorin was supposed to be doing. A study published in April of 2007 showed that “ultrasonography of the common carotid arteries performed at entry and 24 months later showed a significant decrease in intima-media thickness [of the carotid artery] with folate supplementation.” Then, in June of 2007 the Lancet published a startling study showing that folic acid could reduce the risk of a first stroke by 18%. These are the results Vytorin was trying to produce but couldn’t as toxic poisons don’t ever produce health. Folic acid is the hero. Vytorin belongs in the trash with the rest of the statin Class of drugs aka HMG-CoA reductase inhibitors, that are used to lower cholesterol levels by inhibiting the HMG-CoA reductase enzyme that plays a central role in liver function and cholesterol production. garbage.
More Health Freedom News
Loading Content...View complete Health Freedom News Archives